Advertisement

Topics

Latest "ETEX Corporation" News Stories

17:26 EST 13th November 2018 | BioPortfolio

Here are the most relevant search results for "ETEX Corporation" found in our extensive news archives from over 250 global news sources.

More Information about ETEX Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ETEX Corporation for you to read. Along with our medical data and news we also list ETEX Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of ETEX Corporation Companies for you to search.

Showing "ETEX Corporation" News Articles 1–25 of 522

Tuesday 13th November 2018

Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the filing of the Joint Terms of Merger

Press release  REGULATED INFORMATION Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the filing of the common draft terms of the cross-border merger (Joint Terms of Merger) and availability of the merger documentation. Seneffe, Belgium, November 13, 2018. BEBIG announced the filing on 8 November...


Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer

Press release Malmö, November 13, 2018 Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer. Per Persson comes directly from the role as Chief Commercial Officer of Acarix. Christian Lindholm, who has served as interim CEO since February 2018, resumes his role as Chief Financial Officer. The changes are effective immediat...

Bavarian Nordic - Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program

COPENHAGEN, Denmark, November 13, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that the share buy-back program, which was announced and initiated on November 9, 2018, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the Europea...


Inventiva: 2018 third quarter financial update

                                                Inventiva: 2018 third quarter financial update[1] Cash and cash equivalents[1]  at €68.1 million as of September 30, 2018  Revenues[1] for the first nine months of 2018 in line with projections at €2.3 million Daix (France), November 13, 2018 - Inventiva S.A. ("Invent...

Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System

Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease DUBLIN - November 13, 2018 - Medtronic plc (NYSE:MDT) today announced it has received CE Mark approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of all lesions of the descending thoracic aorta, including...

Astrotech Reports First Quarter of Fiscal Year 2019 Financial Results

Astrotech Corporation (NASDAQ: ASTC) reported its financial results for the first quarter of fiscal year 2019 ended September 30, 2018. Astrotech’s 1st Detect subsidiary recently accomplished significant milestones by being accepted by both the U.S. Transportation Security Agency (TSA) and the European Civil Aviation Conference (ECAC) for testin...

LIDDS receives approval from MPA to start Phase I study NZ-DTX-001

The Swedish Medical Product Agency has approved a first-in-human study, NZ-DTX-001, in which solid tumors will be treated with NanoZolid combined with docetaxel. This is LIDDS' second clinical project and will initially include patients at Karolinska University Hospital in Sweden. The Phase I study will assess the safety and tolerability of intratumoral treatment of patients with advan...

Ambu A/S: Annual Report 2017/18 (Earnings release)

Ambu ends the year with 15% organic growth and an EBIT margin of 21.6%. Following a 2.5 percentage point EBIT margin increase, Ambu is on track to realising the targets of its 2020 strategy. "We have now come to the end of the first year of our three-year strategy period, and we have created solid growth in our business. Our key figures and ratios are sa...

FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer

F. Hoffmann-La Roche Ltd / FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Triple-negative breast cancer is an aggressive disea...

Kiadis Pharma to present at upcoming investor conferences in November 2018

    Kiadis Pharma to present at upcoming investor conferences in November 2018 Amsterdam, The Netherlands, November 13, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it is scheduled to present at the following investor conferences in Novembe...

Monday 12th November 2018

ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update

Conference call and webcast scheduled for Tuesday, November 13 at 14:30 CET/8:30 am EST  Phase 3 trial for eryaspase in second line pancreatic cancer enrolling patients Phase 2 trial in triple-negative breast cancer to enroll patients by year end Cash position of €146.9 million ($170 million) as of September 30, 2018 LYON, France and CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) --...

Enzymatica AB: Prospectus for Enzymatica's rights issue with preferential rights for existing shareholders published

Press release November 12, 2018 NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEELAND OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. Pros...

Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences

Press release - No. 23 / 2018 Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences Copenhagen, November 12, 2018 - Britt Meelby Jensen, President and Chief Executive Officer of Zealand Pharma, will attend the Jefferies Healthcare Conference held November 14-15, 2018 in London, and the Bryan, Garnier & Co Annual Healthcare Conference held No...

Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal Year 2019

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae based, high-value nutrition and health products, announced financial results for the second quarter and first six months of fiscal year 2019, ended September 30, 2018. Second Quarter Fiscal 2019 For the second quarter of fiscal 2019 compared to the second qu...

Innate Pharma presented translational data from the Phase II of monalizumab and cetuximab at SITC

SITC 2018: FURTHER ANALYSES OF THE PHASE II STUDY OF THE COMBINATION OF MONALIZUMAB AND CETUXIMAB IN HEAD AND NECK PATIENTS SHOW ENCOURAGING SURVIVAL DATA IN BOTH SUBGROUPS OF IO-NAÏVE AND IO-PRETREATED SCCHN PATIENTS These data support the advancement of the clinical program, starting with the enrollment of an additional cohort of patients who received both prior platinum-bas...

Sunday 11th November 2018

New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Novartis International AG / New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enala...

Friday 9th November 2018

Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2019

DUBLIN - November 9, 2018 - Medtronic plc (NYSE:MDT) announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for t...

Bavarian Nordic Announces Interim Results for the First Nine Months of 2018

COPENHAGEN, Denmark, November 9, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results in line with guidance for the first nine months of 2018 and business progress for the third quarter of 2018. Highlights A Biologics License Application for MVA-BN® smallpox vaccine (formerly IMVAMUNE®) was submitted to the U.S. Food and Drug Admini...

DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

Montrouge, France, November 9, 2018 DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting Three abstracts on Viaskin Peanut accepted for oral presentation DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage

ESPERITE (ESP) expects publication of Annual Report 2017 before 17 November 2018

Amsterdam, The Netherlands - 09 November 2018 Esperite announces that the preparation of its Annual Report 2017 is nearly finalized and expects the publication of its Annual Report 2017 before 17 November 2018. About ESPERITEESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.To learn m...

Thursday 8th November 2018

Global MoistureResistant Plasterboards Market Status and Outlook 20182025 [Report Updated: 14082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

EssilorLuxottica: Conditions for obtaining or consulting the documents prepared for the Ordinary and Extraordinary General Meeting of November 29, 2018

Conditions for obtaining or consulting the documents prepared for the Ordinary and Extraordinary General Meeting of November 29, 2018 PDF version of the news release Charenton-le-Pont, France (November 8, 2018 - 6:00 pm) - Shareholders are advised that an Ordinary and Extraordinary General Meeting will be held on Thursday, November 29, 2018 at 10:30 a.m. CET at the Espace G...

Medtronic Delivers Significant Progress on Global Corporate Citizenship Efforts

2018 Integrated Performance Report Shows Improvement on Environmental Stewardship and Diversity Aspirational Goals DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, is pleased to announce its fiscal year 2018 (FY18) Integrated Performance Report. The 2018 Integrated Performance Report addresses issues critical to the company and its sta...

Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018

Press Release 8 November 2018 Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018 The Extraordinary General Meeting (the "EGM") of Immunicum AB (publ), reg. no 556629-1786, was held today. The EGM resolved to approve both the Board of Directors' resolution on a directed share issue and to approve the Board of Directors' resolution ...

Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication

FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high bl...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks